Japan’s recent Upper House election delivered a stinging defeat for the ruling Liberal Democratic Party (LDP) and junior coalition partner…
BUSINESS
Glaucoma Drug Gla-Alpha Approved in Singapore: Kowa
Kowa said on June 30 that it has won regulatory approval in Singapore for its combination eye drop Gla-Alpha (ripasudil + brimonidine) for the treatment of open angle glaucoma and ocular hypertension. The approval was granted on June 25.According to…
To read the full story
BUSINESS
- Takeda Sees Limited Tariff Exposure as US Remains Strategic Priority
July 31, 2025
- Astellas Assembles Task Team to Assess US Tariff Risks
July 31, 2025
- Lilly Launches Higher-Dose Trulicity in Japan for Type 2 Diabetes
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
- Gene Therapy Deaths Spur Strategic Rethink among Biotechs, Merck Exec Notes Investor Caution
July 30, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…